

COVINGTON & BURLING LLP

1201 PENNSYLVANIA AVENUE NW WASHINGTON
WASHINGTON, DC 20004-2401 NEW YORK
TEL 202.662.6000 SAN FRANCISCO
FAX 202.662.6291 LONDON
WWW.COV.COM BRUSSELS

PATRICK S. DAVIES
TEL 202.662.5274
FAX 202.778.5274
PDAVIES@COV.COM

April 9, 2008

CONFIDENTIAL TREATMENT REQUESTED

DELIVERED BY HAND

The Honorable John D. Dingell
Chairman
United States House of Representatives
Committee on Energy and Commerce
Washington, DC 20515-6115

The Honorable Bart Stupak
Chairman
United States House of Representatives
Committee on Energy and Commerce
Subcommittee on Oversight and Investigations
Washington, DC 20515-6115

Re: Request to Schering-Plough Corporation and Merck & Co., Inc.

Dear Chairman Dingell and Chairman Stupak:

This letter constitutes a supplemental response on behalf of Schering-Plough Corporation (“Schering-Plough”), Merck & Co., Inc. (“Merck”), and Merck/Schering-Plough Pharmaceuticals (collectively, “M/SP Pharmaceuticals”) to your requests for certain documents and information related to the ENHANCE clinical trial (collectively, the “Requests”).

M/SP Pharmaceuticals continues to work diligently to gather the documents and information sought in the Requests, and will continue to produce information and documents on a rolling basis in accordance with our discussions and agreement with the Committee.

As before, we request that the Committee treat this letter and any subsequent information provided in response to the Requests as confidential and that the Committee provide us with notice and an opportunity to object prior to making any portion of our response public.

COVINGTON & BURLING LLP

The Honorable John D. Dingell
The Honorable Bart Stupak
April 9, 2008
Page 2

We are producing with this supplemental response approximately 2,070 documents (19,800 pages) responsive to various Committee requests. For ease of reference, we list here the requests to which the documents are responsive and the corresponding Bates label ranges. Please note that documents may be responsive to more than one request; the Bates ranges as provided are merely rough guides to the subject matter of the documents.

<u>Congressional Request</u>	<u>Bates Range</u>
1. Records relating to the ENHANCE trial generated by members of the outside panel (Request No. 4, December 11, 2007)	MSPP 140944 - MSPP 140950
2. All records of communications between Dr. Kastelein and Schering-Plough and Merck, as well as all communications between Dr. Kastelein and members of the outside advisory panel (namely, J. Robin Crouse, Gregory W. Evans, David G. Orloff, Michiel L. Bots, and James H. Stein) (Request No. 1, January 16, 2008)	MSPP 140951 - MSPP 140955; MSPP 153840 - MSPP 153925
3. All records relating to the January 14, 2008 press release announcing the ENHANCE results (Request No. 2, January 16, 2008)	MSPP 140956 - MSPP 141033; MSPP 153926 - MSPP 154009
4. All records related to advertising for Vytorin (Request Nos. 3a - 3d, January 16, 2008)	MSPP 141034 - MSPP 152333; MSPP 154010 - MSPP 158449
5. Records of all briefings to corporate officers of Schering-Plough or Merck relating to the ENHANCE trial (Request No. 6, January 18, 2008)	MSPP 152334 - MSPP 153217; MSPP 158450 - MSPP 160247
6. Financial and contractual records relating to the division of revenue from Vytorin between Schering-Plough and Merck (Request No. 2, January 18, 2008)	MSPP 160248 - MSPP 160250


COVINGTON & BURLING LLP

The Honorable John D. Dingell
The Honorable Bart Stupak
April 9, 2008
Page 3

- | | |
|--|---|
| 7. All records relating to M/SP Pharmaceuticals' association with the American Heart Association ("AHA") and the American College of Cardiology ("ACC"), including financial records relating to M/SP Pharmaceuticals' association with the AHA, the ACC and the individual leaders of those organizations, as well as records relating to the AHA and ACC press releases of January 15, 2008 (Request Nos. 1 - 4, January 24, 2008) | MSPP 153218 - MSPP 153320;
MSPP 160251 - MSPP 160308 |
| 8. Records relating to the data reviewed by biostatisticians (Request No. 2, February 11, 2008) | MSPP 153321 - MSPP 153556 |
| 9. Records of any and all versions of ENHANCE protocols, SAPs, Operator Manuals and Reader Manuals (Request No. 3, February 11, 2008) | MSPP 153557 - MSPP 153796 |
| 10. Communications with FDA relating to the ENHANCE protocol and SAP (Request No. 4, February 11, 2008) | MSPP 153797 - MSPP 153800;
MSPP 160309 - MSPP 160310 |
| 11. Records relating to the Cafepharm.com posts (Request No. 3, February 11, 2008) | MSPP 153801 - MSPP 153839;
MSPP 160311 - MSPP 160735 |

Please feel free to contact us if you have any questions regarding this response.

Sincerely,

By: 
Patrick S. Davies
*Counsel to Schering-Plough
Corporation, Merck & Co., Inc., and
Merck/Schering-Plough
Pharmaceuticals*

Enclosures